Immatics N.V
IMTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.27B
Close$
$-2.63
127.7% downside
Current Fair Value
127.7% downsideOvervalued by 127.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.27 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.54 |
| Beta | 1.32 |
| Outstanding Shares | 136,680,065 |
Return
| Return on Equity | -50.26% |
|---|---|
| Return on Assets | -41.35% |
| Return on Invested Capital | -53.45% |
Valuation & Multiples
| P/E Ratio | -5.13 |
|---|---|
| PEG | 52.9 |
| Price to Sales | - |
| Price to Book Ratio | 4.75 |
| Enterprise Value to Revenue | 25.34 |
| Enterprise Value to EBIT | -4.62 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$11.90 M
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$12.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 2.00% |
|---|---|
| Total Calls | 22,600▼ 98.68% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.35%▼ 2.74% |
|---|---|
| Total Invested | $1.06B▼ 0.28% |
| Investors Holding | 85▲ 5.00% |
ESG Score
No data
About Immatics N.V
2,020 employeesImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is th...